[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599827":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":98,"collaborators":100,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":109,"sex":115,"minAge":116,"maxAge":10,"enrollmentInfo":117,"targetDuration":120,"studyType":121,"phases":10,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PELICAN population",null,"Patients with either hormone-sensitive (HSPC) or castration-resistant (CRPC) prostate cancer",[13],"Radiation: PSMA PET\u002FCT scan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"RADIATION","PSMA PET\u002FCT scan","All Patients undergoing PSMA PET for pre-treatment disease staging with different radiotracers (\\[68Ga\\]Ga-PSMA-11, \\[18F\\]-DCFPyL, \\[18F\\]-PSMA-1007).",[9],[21],{"name":22,"affiliation":5,"role":23},"Andrea Farolfi","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Andrea Farolfi, MD","CONTACT","+390512143959","andrea.farolfi@aosp.bo.it",{"name":31,"role":27,"phone":28,"phoneExt":10,"email":32},"Andrea Di Giorgio, MD","andrea.digiorgio@live.it",[34,52,67,83],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":38,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna","RECRUITING","Bologna","Italy","40138","IT",{"type":42,"coordinates":43},"Point",[44,45],11.33875,44.49381,{"lat":45,"lon":44},[48,49,50],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":26,"role":23,"phone":10,"phoneExt":10,"email":10},{"name":31,"role":51,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"facility":53,"status":36,"city":54,"state":38,"zip":55,"country":38,"countryCode":40,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Azienda Ospedaliera Santa Croce e Carle - ospedale Santa Croce","Cuneo","12100",{"type":42,"coordinates":57},[58,59],7.54828,44.39071,{"lat":59,"lon":58},[62,66],{"name":63,"role":27,"phone":64,"phoneExt":10,"email":65},"Virgini Liberini, MD","+390171641111","v.liberini@gmail.com",{"name":63,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":68,"status":36,"city":69,"state":38,"zip":70,"country":38,"countryCode":40,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"U.O. Medicina Nucleare, IRCCS Ospedale Policlinico San Martino","Genova","16131",{"type":42,"coordinates":72},[73,74],11.87211,45.21604,{"lat":74,"lon":73},[77,80,82],{"name":78,"role":27,"phone":79,"phoneExt":10,"email":10},"Matteo Bauckneht, MD","+39010555 4812",{"name":10,"role":27,"phone":10,"phoneExt":10,"email":81},"matteo.bauckneht@gmail.com",{"name":78,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":84,"status":36,"city":85,"state":38,"zip":86,"country":38,"countryCode":40,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"UOC Medicina Nucleare, AOU Policlinico G.Martino","Messina","98125",{"type":42,"coordinates":88},[89,90],15.55256,38.19394,{"lat":90,"lon":89},[93,97],{"name":94,"role":27,"phone":95,"phoneExt":10,"email":96},"Riccardo Laudicella, MD","+390902212841","riccardo.laudicella@unime.it",{"name":94,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":22,"investigatorTitle":99,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"MD",[101,103,105],{"name":102,"class":6},"Ospedale Policlinico San Martino",{"name":104,"class":6},"Ospedale Santa Croce-Carle Cuneo",{"name":106,"class":6},"Azienda Ospedaliera Universitaria Policlinico \"G. Martino\"","100599827","psma-pet-for-treatment-response-evaluation-of-systemic-therapies-in-prostate-cancer-pelican-100599827",false,"NCT07089550","PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)","PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN), an Italian Multicenter Study","PELICAN","Inclusion Criteria:\n\n* Histological diagnosis of advanced prostate cancer (excluding neuroendocrine carcinoma);\n* Patients undergoing PSMA PET for pre-treatment disease staging;\n* Candidates to receive one or more of the following systemic therapies, in combination or alone: abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, olaparib, radiotherapy, lutetium-177-PSMA, actinium-225-PSMA;\n* Provision of signed informed consent for study participation and data handling.\n\nExclusion Criteria:\n\n* Inability to remain supine and still for the PET\u002FCT image acquisition;\n* Prostate cancer with a known significant neuroendocrine component;\n* Presence of another concurrent malignancy, with the exception of non-melanoma skin cancer.","MALE","18 Years",{"count":118,"type":119},1300,"ESTIMATED","2 Years","OBSERVATIONAL","This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies.\n\nThe primary goal is to identify prognostic factors derived from PSMA PET imaging. These factors include the number of cancer lesions, the size of the tumor, and measurements known as SUVmax and SUVmean. By identifying these factors, the investigators aim to better group patients and predict those who may have a less favorable outcome. While PSMA PET imaging is highly accurate in locating cancer sites within the body, its ability to predict treatment response has not yet been thoroughly studied in a prospective manner for this patient population.\n\nThis study will assess the predictive role of PSMA PET imaging and its ability to forecast treatment response across a range of systemic therapies, including hormone therapy and chemotherapy, in patients with both hormone-sensitive (HSPC) and castration-resistant (CRPC) prostate cancer.",[124,125],"PSMA Positive Tumors or Tumor Tissues","Prostate Cancer Metastatic",[127,128,129],"PSMA PET\u002FCT","mCRPC","mHSPC","2026-02-19",{"date":132,"type":133},"2026-02-20","ACTUAL",{"date":135,"type":133},"2025-04-02",{"date":137,"type":119},"2034-04-26",{"name":5,"class":6},4]